



MAR 23 2007

**Section 5
510(k) Summary**

K070468

Section 807.92(a)

(1) Submitter

Implant Sciences Corp.
107 Audubon Road #5
Wakefield, MA 01880

Tel: 781.246.0700
Fax: 781.246.1167

Establishment Registration No.: 1226547

Contact Person: Matthew Hollows
Director, Brachytherapy Products
e-mail: mhollows@implantsciences.com

(2) Device Name:

Classification Name: Radionuclide Brachytherapy Source (892.5730) (90 KXK)

Common or Usual Name: Brachytherapy Source Assembly

Proprietary Name: Implant Sciences Corp. Model HDR-4454

(3) Legally Marketed Predicate Devices:

Implant Sciences Corp. Model HDR-4140, cleared under 510(k) number K042864 dated 06 January 2005

(4) Description of Implant Sciences Corp. Model HDR-4454 ¹⁶⁹Ytterbium Brachytherapy Source:

Implant Sciences Corp. Model HDR-4454 is a singly-encapsulated ¹⁶⁹Ytterbium Brachytherapy Source. It consists of a stainless steel capsule containing solid radioactive ¹⁶⁹Ytterbium pellets. The pellets are sealed in a stainless steel capsule that is attached to a cable to permit manipulation by the remote afterloading system.

(5) Intended Use

The intended use of Implant Sciences Corp. Model HDR 4454 Brachytherapy Source is for the treatment of cancer by temporary interstitial, intracavitary, intraluminal, intraoperative or surface irradiation.

(6) Technological Characteristics:

Implant Sciences Corp. Model HDR-4454 ¹⁶⁹Ytterbium Brachytherapy Source is similar to the predicate high dose rate brachytherapy source, Model HDR-4140 (K042864) that utilizes photons from ¹⁶⁹Ytterbium.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
9200 Corporate Blvd.
Rockville MD 20850

Mr. Matthew Hollows
Director of Brachytherapy Products
Implant Sciences Corporation
107 Audobon Road #5
WAKEFIELD MA 01880

MAR 23 2007

Re: K070468
Trade/Device Name: Implant Sciences Corp. Model HDR-4454 ¹⁶⁹Ytterbium
Brachytherapy Source
Regulation Number: 21 CFR §892.5730
Regulation Name: Radionuclide brachytherapy source
Regulatory Class: II
Product Code: KXX
Dated: February 9, 2007
Received: February 21, 2007

Dear Mr. Hollows:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.



Protecting and Promoting Public Health

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.


This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at one of the following numbers, based on the regulation number at the top of this letter:

21 CFR 876.xxxx	(Gastroenterology/Renal/Urology)	240-276-0115
21 CFR 884.xxxx	(Obstetrics/Gynecology)	240-276-0115
21 CFR 892.xxxx	(Radiology)	240-276-0120
Other		240-276-0100

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>

Sincerely yours,



Nancy C. Brogdon
Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

510(k) Number: K070468

Device Name: Implant Sciences Corp. Model HDR-4454 ¹⁶⁹Ytterbium Brachytherapy Source

Indications for Use:

Implant Sciences Model HDR 4454 Source Assembly, with individual activity up to 27Ci, is indicated for temporary interstitial, intracavitary, intraluminal or intraoperative or surface application to treat selected localized tumors. This source can be used as primary treatment for a variety of anatomical sites commonly treated with high dose rate brachytherapy, including the cervix, vagina, endometrium, rectum, esophagus, bronchus, head and neck, bile duct brain, skin, prostate, lung, pancreas, and breast and for treatment of sarcomas and for intraoperative radiation therapy.

This source may be used concurrently with or following treatment with other interventions, such as external beam radiation therapy, hyperthermia or chemotherapy.

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use X
(Per 21 CFR 801.109)

OR

Over-The-Counter Use _____

(Optional Format 1-2-96)

David A. Bergman
(Division Sign-Off)
Division of Reproductive, Abdominal, and
Radiological Devices
510(k) Number K070468